
Revive Therapeutics Ltd.
Condensed Interim Consolidated Financial Statements
Three and Nine Months Ended March 31, 2022 and
2021
(Expressed in Canadian Dollars)
(Unaudited)

Notice to Reader

The accompanying unaudited condensed interim consolidated financial statements of Revive Therapeutics Ltd. (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

Revive Therapeutics Ltd.

Condensed Interim Consolidated Statements of Financial Position

(Expressed in Canadian dollars)

(Unaudited)

	March 31, 2022	June 30, 2021
ASSETS		
Current assets		
Cash and cash equivalents	\$ 5,286,879	\$ 16,599,663
HST receivable	35,870	33,281
Lease receivable (note 4)	107,565	93,504
Prepaid expenses	73,538	68,213
Total current assets	5,503,852	16,794,661
Non-current assets		
Investments (note 5)	250,000	250,000
Equipment (note 7)	1,983	2,416
Lease receivable (note 4)	178,984	259,323
Intangible assets (note 6)	12,500,000	12,500,000
Total non-current assets	12,930,967	13,011,739
Total assets	\$ 18,434,819	\$ 29,806,400
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued liabilities (notes 8 and 17)	\$ 2,907,318	\$ 509,425
Lease liability (note 10)	102,815	88,108
Total current liabilities	3,010,133	597,533
Non-current liabilities		
Lease liability (note 10)	188,742	267,732
Statute barred liabilities (note 9)	74,876	74,412
Loan payable (note 11)	60,000	60,000
Total liabilities	3,333,751	999,677
Shareholders' equity		
Share capital (note 12)	42,910,262	42,430,389
Warrants and broker and finder warrants (notes 13 and 14)	11,226,539	11,425,193
Contributed surplus (note 15)	12,395,485	11,390,991
Accumulated deficit	(51,431,218)	(36,439,850)
Total shareholders' equity	15,101,068	28,806,723
Total liabilities and shareholders' equity	\$ 18,434,819	\$ 29,806,400

Nature of operations and going concern (note 1)

Approved on behalf of the Board:

"Michael Frank", Director

"Andrew Lindzon", Director

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Revive Therapeutics Ltd.

Condensed Interim Consolidated Statements of Comprehensive Loss

(Expressed in Canadian dollars)

(Unaudited)

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2022	2021	2022	2021
Expenses				
Research costs (notes 6 and 17)	\$ 5,708,074	\$ 2,962,636	\$ 12,791,819	\$ 4,233,162
Stock-based compensation (notes 15 and 17(b))	-	204,939	1,037,561	4,014,060
Office expenses (note 18)	37,626	393,782	174,392	853,464
Consulting fees (note 17)	201,208	553,801	723,627	1,875,020
Professional fees (note 17(a)(i)(ii))	75,296	152,533	261,743	471,102
Depreciation and amortization (notes 6 and 7)	144	193	433	581
Comprehensive loss before the below items:	\$ 6,022,348	\$ 4,267,884	\$ 14,989,575	\$ 11,447,389
Accretion of lease liability (note 10)	15,338	19,334	49,238	60,559
Finance income on sub-lease (note 4)	(14,647)	(18,850)	(47,445)	(59,305)
Gain on disposition of investments (note 5)	-	-	-	(198,846)
Unrealized loss on investments	-	-	-	17,500
Comprehensive loss for the period	\$ (6,023,039)	\$ (4,268,368)	\$ (14,991,368)	\$ (11,267,297)
Comprehensive loss per share - basic and diluted (note 16)	\$ (0.02)	\$ (0.01)	\$ (0.05)	\$ (0.05)
Weighted average common shares outstanding - basic and diluted	320,108,413	289,657,854	319,216,669	249,057,876

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Revive Therapeutics Ltd.

Condensed Interim Consolidated Statements of Cash Flows
(Expressed in Canadian dollars)
(Unaudited)

Nine Months Ended March 31,	2022	2021
Cash flow from operating activities		
Comprehensive loss for the period	\$ (14,991,368)	\$ (11,267,297)
Adjustments for:		
Depreciation and amortization	433	581
Stock-based compensation	1,037,561	4,014,060
Gain on disposition of investments	-	(198,846)
Settlement of trade debt through issuance of shares	40,000	980,300
Accretion of lease liability	49,238	60,559
Finance income on sub-lease	(47,445)	(59,305)
Unrealized loss on investments	-	17,500
Foreign exchange loss	464	11,725
Net change in non-cash working capital:		
HST receivable	(2,589)	(3,910)
Prepaid expenses	(5,325)	401,687
Accounts payable and accrued liabilities	2,397,893	218,995
Net cash and cash equivalents used in operating activities	(11,521,138)	(5,823,951)
Investing activities		
Purchase of intangible asset	-	(3,000,000)
Proceeds from sale of investment	-	281,346
Net cash and cash equivalents used in investing activities	-	(2,718,654)
Financing activities		
Proceeds from exercises of warrants and broker warrants	166,152	4,651,811
Proceeds from private placement, net of costs	-	21,013,270
Proceeds from exercise of stock options	42,000	518,875
Lease payments	(113,521)	(111,747)
Proceeds from sublease	113,723	112,660
Net cash and cash equivalents provided by financing activities	208,354	26,184,869
Net change in cash and cash equivalents	(11,312,784)	17,642,264
Cash and cash equivalents, beginning of period	16,599,663	1,381,483
Cash and cash equivalents, end of period	\$ 5,286,879	\$ 19,023,747

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Revive Therapeutics Ltd.

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

(Expressed in Canadian dollars)

(Unaudited)

	Share capital		Warrants and broker and finder warrants	Contributed surplus	Accumulated deficit	Total shareholders' equity
	Number of shares	Amount				
Balance, June 30, 2020	199,889,511	\$ 19,126,095	\$ 1,403,051	\$ 3,220,931	\$(16,321,048)	\$ 7,429,029
Common shares issued in private placement	46,920,000	23,460,000	-	-	-	23,460,000
Valuation of warrants issued in private placement	-	(9,895,659)	9,895,659	-	-	-
Valuation of finder warrants issued in private placement	-	(1,947,698)	1,947,698	-	-	-
Transaction costs in private placements	-	(1,321,234)	(1,125,496)	-	-	(2,446,730)
Common shares issued for exercise of warrants	53,095,598	5,526,477	(1,082,643)	-	-	4,443,834
Common shares issued for exercise of broker warrants	4,159,550	477,239	(269,262)	-	-	207,977
Fair value of warrants issued upon exercise of broker warrants	-	(676,318)	676,318	-	-	-
Common shares issued for exercise of stock options	2,500,000	901,864	-	(382,989)	-	518,875
Common shares issued for settlement of debt	3,827,425	2,705,746	-	-	-	2,705,746
Common shares issued for intangible asset	6,666,667	4,000,000	-	-	-	4,000,000
Stock-based compensation (note 15)	-	-	-	4,014,060	-	4,014,060
Net loss for the period	-	-	-	-	(11,267,297)	(11,267,297)
Balance, March 31, 2021	317,058,751	\$ 42,356,512	\$ 11,445,325	\$ 6,852,002	\$(27,588,345)	\$ 33,065,494
Balance, June 30, 2021	317,958,751	\$ 42,430,389	\$ 11,425,193	\$ 11,390,991	\$(36,439,850)	\$ 28,806,723
Common shares issued for exercise of warrants	2,134,600	337,270	(187,848)	-	-	149,422
Common shares issued for exercise of broker warrants	334,600	27,536	(10,806)	-	-	16,730
Common shares issued for exercise of stock options	150,000	75,067	-	(33,067)	-	42,000
Common shares issued for settlement of debt	100,000	40,000	-	-	-	40,000
Stock-based compensation (note 15)	-	-	-	1,037,561	-	1,037,561
Net loss for the period	-	-	-	-	(14,991,368)	(14,991,368)
Balance, March 31, 2022	320,677,951	\$ 42,910,262	\$ 11,226,539	\$ 12,395,485	\$(51,431,218)	\$ 15,101,068

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements

For the Three and Nine Months Ended March 31, 2022

(Expressed in Canadian dollars)

(Unaudited)

1. Nature of Operations and Going Concern

Revive Therapeutics Ltd. (the "Company" or "Revive") was incorporated under the Business Corporations Act (Ontario) on March 27, 2012. The Company's shares traded on the TSX Venture Exchange (the "Exchange") under the symbol "RVV" and the Frankfurt Stock Exchange in Germany under the symbol "31R". Revive also trades in the United States under pink sheets as RVVTF. On July 19, 2019, the Company received final approval to list its common shares on the Canadian Securities Exchange (the "CSE"), and to voluntarily delist its common shares from the Exchange. The common shares commenced trading on the CSE at the market opening on July 23, 2019. The Company is focused on the development and commercialization of drugs for underserved medical needs. The Company's registered and legal office is located at The Canadian Venture Building, 82 Richmond Street East, Toronto, Ontario M5C 1P1.

These unaudited condensed interim consolidated financial statements were prepared on a going concern basis of presentation, which assumes that the Company will continue operations for the foreseeable future and be able to realize the carrying value of its assets and discharge its liabilities and commitments in the normal course of business. To date, the Company has not earned revenue and has an accumulated deficit of \$51,431,218 as at March 31, 2022 (June 30, 2021 - \$36,439,850). As at March 31, 2022, the Company had cash and cash equivalents of \$5,286,879 (June 30, 2021 - \$16,599,663) and a working capital of \$2,493,719 (June 30, 2021 - working capital of \$16,197,128). The Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing and/or achieve profitable operations in the future. Management is aware, in making its assessment, of material uncertainties related to events or conditions that cast significant doubt upon the Company's ability to continue as a going concern. These consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. These adjustments could be material. Management is actively pursuing funding options, being financing and alternative funding options, required to meet the Company's requirements on an ongoing basis.

The Company's operations could be significantly adversely affected by the effects of a widespread global outbreak of a contagious disease, including the recent outbreak of respiratory illness caused by Novel Coronavirus ("COVID-19"). The Company cannot accurately predict the impact COVID-19 will have on its operations and the ability of others to meet their obligations with the Company, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect the Company's operations and ability to finance its operations.

2. Significant Accounting Policies

Statement of compliance

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full audited annual financial statements.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRS issued and outstanding as of May 27, 2022, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements as at and for the year ended June 30, 2021, except as noted below. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the year ending June 30, 2022 could result in restatement of these unaudited condensed interim consolidated financial statements.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended March 31, 2022
(Expressed in Canadian dollars)
(Unaudited)

2. Significant Accounting Policies (continued)

New interpretations issued but not yet effective

Certain new accounting standards and interpretations have been published that are not mandatory for the current period and have not been early adopted. These standards are not expected to have a material impact on the Company in the current or future reporting periods.

3. Fair Value Measurements

The following table illustrates the classification of the Company's financial instruments recorded at fair value within the fair value hierarchy as at March 31, 2022 and June 30, 2021:

March 31, 2022	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$ 5,286,879	\$ -	\$ -	\$ 5,286,879
Investments	-	-	250,000	250,000

June 30, 2021	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$ 16,599,663	\$ -	\$ -	\$ 16,599,663
Investments	-	-	250,000	250,000

Level 3 hierarchy:

The following table presents the changes in fair value measurement of financial instrument classified as Level 3. The financial instrument is measured at fair value utilizing non-observable market inputs.

Investment at fair value	Opening balance at July 1, 2021	Unrealized loss	Ending balance at March 31, 2022
Herman Holdings Limited ("HHL")	\$ 250,000	\$ -	\$ 250,000

Investment at fair value	Opening balance at July 1, 2020	Unrealized loss	Ending balance at March 31, 2021
HHL	\$ 250,000	\$ -	\$ 250,000

Within Level 3, the Company includes a non-public company investment. The key assumptions used in the valuation of the instrument include (but are not limited to) the value at which a recent financing was done by the investee.

The following table presents the fair value, categorized by key valuation techniques and the unobservable inputs used within Level 3 as at:

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended March 31, 2022
(Expressed in Canadian dollars)
(Unaudited)

3. Fair Value Measurements (continued)

Level 3 hierarchy (continued):

March 31, 2022

Investment name	Valuation technique	Fair value	Unobservable inputs
HHL	recent financing	\$ 250,000	Transaction price

As the valuation of investments for which market quotations are not readily available and are inherently uncertain, the values may fluctuate materially within short periods of time and are based on estimates, and determinations of fair value may differ materially from values that would have resulted if a ready market existed for the investments. As at March 31, 2022, a change in the transaction price of 5% would result in an increase/decrease in the fair value estimate of the investment of approximately \$12,500, keeping all other variables constant.

4. Lease receivable

Balance, June 30, 2020	\$ 425,904
Reduction of lease receivable in settlement of lease liability	(112,660)
Finance income	59,305
Balance, March 31, 2021	\$ 372,549
<hr/>	
Balance, June 30, 2021	\$ 352,827
Reduction of lease receivable in settlement of lease liability	(113,723)
Finance income	47,445
Balance, March 31, 2022	\$ 286,549
<hr/>	
Allocated as:	
Current	\$ 107,565
Non-current	178,984
	\$ 286,549

The underlying sub-lease agreement terminates on August 31, 2024.

5. Investments

Privately-held investment

In connection with the closing of the non-brokered private placement in February 2019, Revive acquired an aggregate of 2,500,000 common shares of HHL at a price of \$0.30 per common share of HHL for gross payment of \$750,000 representing 5% of the issued and outstanding HHL Shares. During the year ended June 30, 2020, the Company recorded an unrealized loss of \$500,000 on investment in HHL common shares and during the three and nine months ended March 31, 2022, the fair value of the investment remained unchanged at \$250,000.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements

For the Three and Nine Months Ended March 31, 2022

(Expressed in Canadian dollars)

(Unaudited)

5. Investments (continued)

Investment in a public company

On February 10, 2020, the Company entered into a supply and collaboration agreement (the "Agreement") with Red Light Holland Financing Inc. ("Red Light"), an arm's length party. Pursuant to the Agreement Red Light will sell to Revive a consistent strain of truffles for the sole purpose of Revive undertaking research and development on the suitability and implementation of its novel cannabinoid delivery technology with respect to the truffles and its extracts. Red Light has also agreed to, upon request, provide Revive with any information, studies, papers and other information it may have pertaining to the truffles which may be deemed to be beneficial to Revive for undertaking the research and development. Revive issued to Red Light an aggregate of 3,000,000 common shares valued at \$195,000 based on Revive's stock price on the date of issuance in consideration of 2,500,000 Red Light shares. During the year ended June 30, 2020, the Company sold 1,250,000 Red Light shares for proceeds of \$142,240 in the Company investment broker's account which were included in cash and cash equivalents on the consolidated statement of financial position as at June 30, 2020. During the year ended June 30, 2021, the Company disposed of all of the Red Light shares for proceeds of \$281,346 and recorded a gain on disposition of investments of \$198,846. During the year ended June 30, 2021, the Company recorded an unrealized loss on investment of \$17,500.

6. Intangible Assets

Cost	Psilocybin	Psilocin	Total
Balance, June 30, 2021 and March 31, 2022	\$ 7,000,000	\$ 5,500,000	\$ 12,500,000

Carrying value	Psilocybin	Psilocin	Total
Balance, June 30, 2021 and March 31, 2022	\$ 7,000,000	\$ 5,500,000	\$ 12,500,000

Psilocin

On March 5, 2020, the Company completed its acquisition of all of the issued and outstanding securities in the capital of Psilocin Pharma Corp. ("Psilocin"), an arm's length party incorporated pursuant to the laws of the Province of Ontario. Psilocin is a specialty psychedelic sciences company focused on the development of Psilocybin-based therapeutics for significant unmet medical needs including rare and orphan indications.

Pursuant to the terms of a share exchange agreement dated March 4, 2020, Revive acquired all of the issued and outstanding securities of Psilocin through the issuance of an aggregate of 55 million common shares in the capital of Revive.

Psilocin was determined not to meet the definition of a business as per IFRS 3 as substantially all of the fair value of Psilocin was concentrated in one asset: its intellectual property. Accordingly, the acquisition was treated as an asset acquisition.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements

For the Three and Nine Months Ended March 31, 2022

(Expressed in Canadian dollars)

(Unaudited)

6. Intangible Assets (continued)

Psilocin (continued)

Details of the allocation of the estimated fair value of identifiable assets acquired and purchase consideration are as follows:

Purchase consideration:	\$ 5,500,000
--------------------------------	--------------

Identifiable net assets acquired:

Intellectual property	\$ 5,500,000
-----------------------	--------------

Psilocin has developed patent-pending formulation and production solutions for the active compound Psilocybin. The process encompassed with its intellectual property cover methods of production of Psilocybin-based formulations. Psilocin has developed formulations to date which include the Hydroxy Line. The line will include PSY-0.1 -Capsules, PSY-0.2 -Sublingual Spray, PSY-0.3 -Gel Cap, PSY-0.4/0.5 -Effervescent Tablets, and PSY-0.6 -Breath Strips. The precisely dosed formulations will work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to U.S. Food and Drug Administration ("FDA") approval in the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and a number of other diseases. Psilocin's range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption.

Psilocin has filed key provisional patent applications with the U.S. Patent and Trademark Office that cover methods of production of Psilocybin-based formulations. Furthermore, Psilocin has a patent-pending portfolio that includes Psilocybin extraction and crystallization methodologies.

The costs of provisional patents and pending applications are not amortized until the patent is approved and are reviewed each reporting period to determine if it is likely that the patent will be successfully granted.

The recoverable amount of Psilocin is determined based on its fair value less cost of disposal. The fair value less cost of disposal is determined based on the market value of the shares issued for the acquisition of Psilocin and management experience of the market. The fair value less cost of disposal is categorized as level 3 in the fair value hierarchy.

Psilocybin

On February 17, 2021, the Company signed an asset purchase agreement (the "Agreement") with PharmaTher Inc. ("PharmaTher") a wholly-owned subsidiary of Newscope Capital Corporation to purchase the full rights to PharmaTher's intellectual property (the "Acquired Assets") pertaining to psilocybin (the "Acquisition").

Pursuant to the Agreement, Revive will pay aggregate consideration of up to \$10 million (the "Purchase Price"). The Purchase Price will be satisfied as follows: (i) \$3 million in cash will be paid on the closing date (paid); (ii) \$4 million will be satisfied through the issuance of securities in the capital of Revive (issued) and (iii) up to \$3 million, in either cash or securities in the capital of Revive, in the event that Revive achieves certain milestones, which include Revive obtaining FDA orphan drug designation for psilocybin in the treatment of stroke, traumatic brain injury, or cancer, the commencement of a Phase 2 clinical trial and the regulatory filing for market authorization, such as U.S. Food and Drug Administration ("FDA") approval. In addition to the Purchase Price, Revive will also pay PharmaTher Holdings Ltd. a low single digit royalty on all future net sales of products derived from the Acquired Assets.

The costs of provisional patents and pending applications are not amortized until the patent is approved and are reviewed each reporting period to determine if it is likely that the patent will be successfully granted.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements

For the Three and Nine Months Ended March 31, 2022

(Expressed in Canadian dollars)

(Unaudited)

6. Intangible Assets (continued)

REV-002

During the three and nine months ended March 31, 2022, the Company incurred \$nil (three and nine months ended March 31, 2021 - \$nil and \$26,151, respectively) in REV-002 research costs for consulting services of clinical trial design and research.

REV-004 and REV-005

During the three and nine months ended March 31, 2022, the Company incurred \$nil (three and nine months ended March 31, 2021 - \$51,036 and \$175,097, respectively) research costs for REV - 004 and \$nil (three and nine months ended March 31, 2021 - \$nil) research costs for REV-005.

CANNABINOIDS

During the three and nine months ended March 31, 2022, the Company incurred \$nil (three and nine months ended March 31, 2021 - \$nil) research costs for cannabinoids.

BUCILLAMINE

Bucillamine is a disease-modifying anti-rheumatic drug, which is prescribed for rheumatoid arthritis in Japan and South Korea. The Company pursued the repurposing of bucillamine as a potential new treatment for gout and cystinuria. The Company entered into a material transfer agreement (“MTA”) with the developer of bucillamine. The Company is exploring the use of Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (COVID-19).

During the three and nine months ended March 31, 2022, the Company incurred \$5,679,651 and \$12,123,141, respectively (three and nine months ended March 31, 2021 - \$2,169,890 and \$3,086,952, respectively) research costs for Bucillamine.

PSILOCYBIN

During the three and nine months ended March 31, 2022, the Company incurred \$28,423 and \$666,213, respectively (three and nine months ended March 31, 2021 - \$55,358 and \$110,358, respectively) research costs for Psilocybin-based formulations.

DRUG DELIVERY TECHNOLOGY

The Company is focused on commercializing novel delivery technologies to effectively deliver psychedelics and cannabinoids through the skin and/or directly into the affected area of the skin, otherwise known as topical delivery and also via the mouth, otherwise known as buccal delivery.

During the three and nine months ended March 31, 2022, the Company incurred \$nil and \$1,362, respectively (three and nine months ended March 31, 2021 - \$125,232 and \$266,369, respectively) research costs for drug delivery technology.

OTHER

During the three and nine months ended March 31, 2022, the Company incurred \$nil and \$1,103, respectively (three and nine months ended March 31, 2021 - \$561,120 and \$568,235, respectively) general research costs not specifically allocated to any particular project.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended March 31, 2022
(Expressed in Canadian dollars)
(Unaudited)

7. Equipment

Cost	Computer Equipment	Office Equipment	Total
Balance, June 30, 2021 and March 31, 2022	\$ 7,171	\$ 7,737	\$ 14,908
Accumulated depreciation	Computer Equipment	Office Equipment	Total
Balance, June 30, 2021	\$ 6,219	\$ 6,273	\$ 12,492
Depreciation during the period	214	219	433
Balance, March 31, 2022	\$ 6,433	\$ 6,492	\$ 12,925
Carrying value	Computer Equipment	Office Equipment	Total
Balance, June 30, 2021	\$ 952	\$ 1,464	\$ 2,416
Balance, March 31, 2022	\$ 738	\$ 1,245	\$ 1,983

8. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities of the Company are principally comprised of amounts outstanding for purchases relating to research and development and general operating activities.

	As at March 31, 2022	As at June 30, 2021
Accounts payable	\$ 2,775,494	\$ 436,021
Accrued liabilities	131,824	73,404
	\$ 2,907,318	\$ 509,425
	As at March 31, 2022	As at June 30, 2021
Less than 1 month	\$ 256,166	\$ 389,003
1 to 3 months	2,554,689	18,526
Greater than 3 months	96,463	101,896
	\$ 2,907,318	\$ 509,425

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended March 31, 2022
(Expressed in Canadian dollars)
(Unaudited)

9. Statute Barred Liabilities

During the year ended June 30, 2020, the Company transferred \$63,511 of accounts payable (the “Statute-barred Claims”) to non-current liabilities on the basis that any claims in respect of the Statute-barred Claims were statute barred under the Limitations Act (Ontario). The Statute-barred Claims relate to expenses billed by third-party vendors. Under IFRS, a financial liability can only be derecognized from the Company’s Statement of Financial Position when it is extinguished, meaning only when the contract is discharged or canceled or expires. The effect of the Limitations Act is to prevent a creditor from enforcing an obligation, but it does not formally extinguish the financial liability under IFRS.

It is the position of management of the Company that the Statute-barred Claims cannot be enforced by the creditors, do not create any obligation for the Company to pay out any cash and do not affect the financial or working capital position of the Company. The Statute-barred Claims are required to be reflected on the Company’s Statement of Financial Position as a result of the current interpretation of IFRS, but they are classified as non-current liabilities as the Company has no intention to pay these Statute-barred Claims and the creditors cannot enforce payment of the Statute-barred Claims.

As at March 31, 2022, the Company had statute-barred liabilities of \$74,876 (June 30, 2021 - \$74,412).

10. Lease Liability

Balance, June 30, 2020	\$ 425,854
Accretion	60,559
Lease payments and settlement of lease receivable	(111,747)
Balance, March 31, 2021	\$ 374,666

Balance, June 30, 2021	\$ 355,840
Accretion	49,238
Lease payments and settlement of lease receivable	(113,521)
Balance, March 31, 2022	\$ 291,557

Allocated as:	
Current	\$ 102,815
Non-current	188,742
	\$ 291,557

The underlying lease agreement terminates on August 31, 2024.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended March 31, 2022 (Expressed in Canadian dollars) (Unaudited)

11. Loan Payable

During the year ended June 30, 2020, the Company applied for the COVID-19 Relief Line of Credit as part of the Government-sponsored Canada Emergency Business Account (CEBA). The credit limit of \$60,000 has an interest rate of 0% until December 31, 2020. On January 1, 2021, the operating line of credit was converted to a 3-year 0% interest term loan, to be repaid by December 31, 2023 of which \$20,000 of the loan will be forgiven if \$40,000 is repaid in full on or before December 31, 2023. If on December 31, 2023 the loan is not repaid, the Company can exercise the option for a 3-year term extension at an interest rate of 5% on the balance over the term extension period. The Company expects to pay the loan prior to December 31, 2023.

On January 12, 2022, the Government of Canada announced that the repayment deadline for CEBA Loans to qualify for partial loan forgiveness is being extended from December 31, 2022 to December 31, 2023 for all eligible borrowers in good standing. Repayment on or before the new deadline of December 31, 2023 will result in loan forgiveness of up to a third of the value of the loans (ie. up to \$20,000 with respect to the CEBA Loans). Conversely, if any such loans are not repaid in full by December 31, 2023, they will automatically renew with a maturity date of December 31, 2025, subject to interest at 5% per annum, commencing on January 1, 2024.

12. Share Capital

a) Authorized share capital

The authorized share capital consists of an unlimited number of common shares. The common shares do not have a par value. All issued shares are fully paid.

b) Common shares issued

As at March 31, 2022, the issued share capital amounted to \$42,910,262 and there were nil shares held in escrow. Changes in issued share capital are as follows:

	Number of Common Shares	Amount
Balance, June 30, 2020	199,889,511	\$ 19,126,095
Common shares issued in private placement	46,920,000	23,460,000
Valuation of warrants issued in private placement	-	(9,895,659)
Valuation of finder warrants issued in private placement	-	(1,947,698)
Transaction costs in private placement	-	(1,321,234)
Common shares issued for exercise of warrants	53,095,598	5,526,477
Common shares issued for exercise of broker warrants	4,159,550	477,239
Fair value of warrants issued upon exercised of broker warrants	-	(676,318)
Common shares issued for exercise of stock options	2,500,000	901,864
Common shares issued for settlement of debt	3,827,425	2,705,746
Common shares issued for intangible asset (note 6)	6,666,667	4,000,000
Balance, March 31, 2021	317,058,751	\$ 42,356,512

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended March 31, 2022
(Expressed in Canadian dollars)
(Unaudited)

12. Share Capital (continued)

b) Common shares issued (continued)

Balance, June 30, 2021	317,958,751	\$ 42,430,389
Common shares issued for exercise of warrants	2,134,600	337,270
Common shares issued for exercise of broker warrants	334,600	27,536
Common shares issued for exercise of stock options	150,000	75,067
Common shares issued for settlement of debt	100,000	40,000
Balance, March 31, 2022	320,677,951	\$ 42,910,262

13. Warrants

The following table reflects the continuity of warrants for the periods ended March 31, 2022 and 2021:

	Number of Warrants	Weighted Average Exercise Price
Balance, June 30, 2020	62,924,266	\$ 0.08
Exercised	(53,095,598)	0.08
Issued	51,079,550	0.65
Balance, March 31, 2021	60,908,218	\$ 0.56
Balance, June 30, 2021	60,108,218	\$ 0.58
Exercised	(2,134,600)	0.07
Issued upon exercise of broker warrants	334,600	0.07
Balance, March 31, 2022	58,308,218	\$ 0.58

The following table reflects warrants issued and outstanding as at March 31, 2022:

Expiry Date and Description	Exercise Price (\$)	Fair Value (\$)	Number of Warrants Outstanding
February 5, 2025	0.07	25,348	4,200,000
March 18, 2023	0.07	250,341	2,314,070
April 14, 2023	0.07	284,970	4,874,148
February 12, 2024	0.70	8,770,163	46,920,000
Transaction costs		(51,981)	
	0.58	9,278,841	58,308,218

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended March 31, 2022
(Expressed in Canadian dollars)
(Unaudited)

14. Broker and Finder Warrants

The following table reflects the continuity of broker and finder warrants for the periods ended March 31, 2022 and 2021:

	Number of Broker Warrants	Weighted Average Exercise Price
Balance, June 30, 2020	4,494,150	\$ 0.05
Exercised	(4,159,550)	0.05
Issued	3,220,000	0.50
Balance, March 31, 2021	3,554,600	\$ 0.46
Balance, June 30, 2021	3,554,600	\$ 0.46
Exercised	(334,600)	0.05
Balance, March 31, 2022	3,220,000	\$ 0.50

The following table reflects broker and finder warrants issued and outstanding as at March 31, 2022:

Expiry Date	Exercise Price (\$)	Fair Value (\$)	Number of Broker Warrants Outstanding
February 12, 2024	0.50	1,947,698	3,220,000
	0.50	1,947,698	3,220,000

15. Stock Options

The Company has granted options for the purchase of common shares to its directors, officers, employees and certain consultants. The purpose of the plan is to attract, retain and motivate these parties by providing them with the opportunity, through share options, to acquire a proprietary interest in the Company and to benefit from its growth. These options are valid for a maximum of 10 years from the date of issue. Vesting terms and conditions are determined by the Board of Directors at the time of the grant. The maximum number of options to be issued under the plan shall not exceed 10% of the total number of common shares issued and outstanding.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended March 31, 2022
(Expressed in Canadian dollars)
(Unaudited)

15. Stock Options (continued)

The following table reflects the continuity of stock options for the periods ended March 31, 2022 and 2021:

	Number of Stock Options	Weighted Average Exercise Price
Balance, June 30, 2020	12,245,709	\$ 0.24
Granted (ii)(iii)(iv)(v)	10,300,000	0.34
Exercised	(2,500,000)	0.21
Balance, March 31, 2021	20,045,709	\$ 0.29
Balance, June 30, 2021	29,105,709	\$ 0.40
Granted (vi)(vii)(viii)(ix)(x)(xi)(xii)	2,150,000	0.60
Exercised	(150,000)	0.28
Balance, March 31, 2022	31,105,709	\$ 0.41

The following table reflects the actual stock options issued and outstanding as at March 31, 2022:

Expiry Date	Exercise Price (\$)	Weighted Average Remaining Contractual Life (years)	Number of Options Outstanding	Number of Options Vested (exercisable)	Grant Date Fair Value
July 9, 2023	0.30	1.27	40,375	40,375	\$ 9,270
January 31, 2024	0.66	1.84	195,000	195,000	87,772
February 10, 2025	0.60	2.87	280,000	280,000	104,450
April 10, 2027	0.28	5.03	165,000	165,000	36,374
November 1, 2022	0.20	0.59	250,000	250,000	31,336
November 29, 2022	0.325	0.67	100,000	100,000	26,368
April 22, 2024	0.17	2.06	125,334	125,334	14,193
December 27, 2029	0.07	7.75	3,150,000	3,150,000	160,082
May 25, 2030 (i)	0.33	8.16	5,100,000	5,100,000	1,638,191
August 6, 2025 (ii)	0.33	3.35	6,000,000	6,000,000	2,148,379
August 12, 2025 (iii)	0.36	3.37	2,500,000	2,500,000	727,961
August 12, 2025 (iv)	0.35	3.37	1,250,000	1,250,000	364,173
August 24, 2025 (v)	0.35	3.40	300,000	300,000	76,789
June 21, 2026	0.35	4.23	9,500,000	9,500,000	4,428,995
July 19, 2026 (vi)	0.60	4.30	100,000	100,000	53,285
August 10, 2026 (vii)	0.60	4.36	200,000	200,000	95,005
August 16, 2026 (viii)	0.60	4.38	200,000	200,000	71,989
November 1, 2026 (ix)	0.60	4.59	1,000,000	1,000,000	518,696
November 15, 2026 (x)	0.60	4.63	400,000	400,000	178,926
November 17, 2026 (xi)	0.60	4.64	100,000	100,000	46,160
November 30, 2026 (xii)	0.60	4.67	150,000	150,000	73,499
			31,105,709	31,105,709	\$ 10,891,893

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements

For the Three and Nine Months Ended March 31, 2022

(Expressed in Canadian dollars)

(Unaudited)

15. Stock Options (continued)

(i) On May 25, 2020, the Company granted certain officers, directors, employees and consultants of the Company 5,175,000 stock options at an exercise price of \$0.33 per share expiring on May 25, 2030. The fair value of the stock options was estimated to be \$1,662,282 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 147.29%; risk-free interest rates of 0.36%; and expected life of 5 years. These options vest as to one half (1/2) of the options on the date of grant and one half (1/2) of the options on the date which is one (1) year from the date of grant. During the three and nine months ended March 31, 2022, \$nil (three and nine months ended March 31, 2021 - \$204,939 and \$623,925, respectively) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(ii) On August 6, 2020, the Company granted an officer of the Company 6,000,000 stock options at an exercise price of \$0.33 per share expiring on August 6, 2025. The fair value of the stock options was estimated to be \$2,148,379 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 155.17%; risk-free interest rates of 0.32%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil (three and nine months ended March 31, 2021 - \$nil and \$2,148,379, respectively) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(iii) On August 12, 2020, the Company granted a consultant of the Company 2,500,000 stock options at an exercise price of \$0.35 per share expiring on August 12, 2025. The fair value of the stock options was estimated to be \$727,960 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 155.24%; risk-free interest rates of 0.41%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil (three and nine months ended March 31, 2021 - \$nil and \$727,960, respectively) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(iv) On August 12, 2020, the Company granted certain consultants of the Company 1,500,000 stock options at an exercise price of \$0.35 per share expiring on August 12, 2025. The fair value of the stock options was estimated to be \$437,007 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 155.24%; risk-free interest rates of 0.41%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil (three and nine months ended March 31, 2021 - \$nil and \$437,007, respectively) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(v) On August 24, 2020, the Company granted a consultant of the Company 300,000 stock options at an exercise price of \$0.35 per share expiring on August 24, 2025. The fair value of the stock options was estimated to be \$76,789 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 155.29%; risk-free interest rates of 0.38%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil (three and nine months ended March 31, 2021 - \$nil and \$76,789, respectively) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(vi) On July 19, 2021, the Company granted a consultant of the Company 100,000 stock options at an exercise price of \$0.60 per share expiring on July 19, 2026. The fair value of the stock options was estimated to be \$53,285 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 155.82%; risk-free interest rates of 0.78%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil and \$53,285, respectively (three and nine months ended March 31, 2021 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements

For the Three and Nine Months Ended March 31, 2022

(Expressed in Canadian dollars)

(Unaudited)

15. Stock Options (continued)

(vii) On August 10, 2021, the Company granted a consultant of the Company 200,000 stock options at an exercise price of \$0.60 per share expiring on August 10, 2026. The fair value of the stock options was estimated to be \$95,005 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 155.37%; risk-free interest rates of 0.90%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil and \$95,005, respectively (three and nine months ended March 31, 2021 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(viii) On August 16, 2021, the Company granted a consultant of the Company 200,000 stock options at an exercise price of \$0.60 per share expiring on August 16, 2026. The fair value of the stock options was estimated to be \$71,990 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 154.67%; risk-free interest rates of 0.81%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil and \$71,990, respectively (three and nine months ended March 31, 2021 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(ix) On November 1, 2021, the Company granted certain consultants of the Company 1,000,000 stock options at an exercise price of \$0.60 per share expiring on November 1, 2026. The fair value of the stock options was estimated to be \$518,696 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 151.13%; risk-free interest rates of 1.51%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil and \$518,696, respectively (three and nine months ended March 31, 2021 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(x) On November 15, 2021, the Company granted certain consultants of the Company 400,000 stock options at an exercise price of \$0.60 per share expiring on November 15, 2026. The fair value of the stock options was estimated to be \$178,926 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 151.25%; risk-free interest rates of 1.48%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil and \$178,926, respectively (three and nine months ended March 31, 2021 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(xi) On November 17, 2021, the Company granted a consultant of the Company 100,000 stock options at an exercise price of \$0.60 per share expiring on November 17, 2026. The fair value of the stock options was estimated to be \$46,160 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 151.26%; risk-free interest rates of 1.48%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil and \$46,160, respectively (three and nine months ended March 31, 2021 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

(xii) On November 30, 2021, the Company granted a consultant of the Company 150,000 stock options at an exercise price of \$0.60 per share expiring on November 30, 2026. The fair value of the stock options was estimated to be \$73,498 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 151.18%; risk-free interest rates of 1.40%; and expected life of 5 years. These options vested immediately upon grant. During the three and nine months ended March 31, 2022, \$nil and \$73,498, respectively (three and nine months ended March 31, 2021 - \$nil) was recorded as stock-based compensation in the consolidated statements of comprehensive loss.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended March 31, 2022 (Expressed in Canadian dollars) (Unaudited)

16. Net Loss per Common Share

The calculation of basic and diluted loss per share for the three and nine months ended March 31, 2022 was based on the loss attributable to common shareholders of \$6,023,039 and \$14,991,368, respectively (three and nine months ended March 31, 2021 - \$4,268,368 and \$11,267,297, respectively) and the weighted average number of common shares outstanding of 320,108,413 and 319,216,669 (three and nine months ended March 31, 2021 - 289,657,854 and 249,057,876, respectively).

Diluted loss per share did not include the effect of 58,308,218 warrants (three and nine months ended March 31, 2021 - 60,908,218), 3,220,000 finder warrants (three and nine months ended March 31, 2021 - 3,554,600) and 31,105,709 stock options (three and nine months ended March 31, 2021 - 20,045,709) as they are anti-dilutive.

17. Related Party Balances and Transactions and Major Shareholders

(a) Related party balances and transactions:

Related parties include the directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2022	2021	2022	2021
Marrelli Support Services Inc. ("Marrelli Support") (i)	\$ 15,359	\$ 16,650	\$ 36,420	\$ 47,480
DSA Corporate Services Inc. and DSA Filing Services Limited (together, known as "DSA") (ii)	\$ 12,402	\$ 19,999	\$ 57,475	\$ 45,668

(i) The Company owed Marrelli Support \$2,349 as at March 31, 2022 (June 30, 2021 - owed \$2,351) for the services of Carmelo Marrelli to act as Chief Financial Officer ("CFO") of the Company. This amount was included in accounts payable and accrued liabilities. The Company has entered into a consulting agreement (the "Marrelli Consulting Agreement") with Marrelli Support and Mr. Marrelli to provide the services of Mr. Marrelli as CFO of the Company. The term of the Marrelli Consulting Agreement commenced on July 14, 2013, and shall continue until terminated by either Mr. Marrelli or the Company. Pursuant to the Marrelli Consulting Agreement, Mr. Marrelli is entitled to receive monthly compensation of \$1,250 per month, and incentive stock option grants on a reasonable basis, consistent with the grant of options to other grantees. In addition, Marrelli Support provides bookkeeping services to the Company. Mr. Marrelli is the Managing Director of Marrelli Support. The amounts charged by Marrelli Support are based on what Marrelli Support usually charges its clients. The Company expects to continue to use Marrelli Support for an indefinite period of time.

(ii) The Company owed DSA \$1,752 as at March 31, 2022 (June 30, 2021 - \$3,706) for corporate secretarial and filing services. This amount was included in accounts payable and accrued liabilities. DSA consists of two private companies beneficially controlled by Carmelo Marrelli, the CFO of the Company. Services were incurred in the normal course of operations for corporate secretarial, electronic filing and news dissemination services. The Company expects to continue to use DSA's services for an indefinite period of time.

Revive Therapeutics Ltd.

Notes to Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended March 31, 2022
(Expressed in Canadian dollars)
(Unaudited)

17. Related Party Balances and Transactions and Major Shareholders (continued)

(b) Remuneration of directors and key management personnel including Chief Executive Officer and Chief Financial Officer of the Company for the periods ended March 31, 2022 and 2021 was as follows:

	Three Months Ended March 31,		Nine Months Ended December 31,	
	2022	2021	2022	2021
Stock-based compensation	\$ -	\$ 138,606	\$ -	\$ 2,570,357
Consulting fees	\$ 113,401	\$ 120,000	\$ 368,401	\$ 300,000

(c) Major shareholders:

As at March 31, 2022, no person or corporation beneficially owns or exercises control or direction over common shares of the Company carrying more than 10% of the voting rights attached to all of the common shares of the Company.

None of the Company's major shareholders have different voting rights other than holders of the Company's common shares.

The Company is not aware of any arrangements, the operation of which may at a subsequent date result in a change in control of the Company. The Company is not directly or indirectly owned or controlled by another corporation, by any government or by any natural or legal person severally or jointly.

18. Office Expenses

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2022	2021	2022	2021
Reporting issuer costs	\$ 28,562	\$ 265,121	\$ 111,697	\$ 306,437
Marketing and promotion	6,660	-	6,660	275,160
Administrative	(8,644)	7,292	41,950	119,607
Insurance	17,792	119,649	54,461	146,489
Travel and accommodation	-	-	-	143
Meals and entertainment	231	225	4,798	630
Bank charges	1,686	1,495	5,665	4,998
Interest income	(8,661)	-	(50,839)	-
	\$ 37,626	\$ 393,782	\$ 174,392	\$ 853,464